09:35 AM EDT, 03/13/2025 (MT Newswires) -- ImmunityBio ( IBRX ) said Thursday that US Urology Partners has begun administering its recombinant Bacillus Calmette-Guerin, or rBCG, in the US as part of an effort to address a shortage of Tice BCG.
The company said the shortage of Tice BCG is a "significant impediment" to treating bladder cancer.
ImmunityBio ( IBRX ) said the US Food and Drug Administration recently authorized ImmunityBio's ( IBRX ) Expanded Access Program for rBCG, and 60 urology centers are preparing to launch the treatment.
The company said it is working with the Serum Institute of India to produce rBCG.
Price: 2.84, Change: -0.03, Percent Change: -1.05